Collegium Pharmaceutical (COLL) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 23.1% versus a loss of 33.5%. Over five years, COLL leads with a +5.3% price change compared with -71.4% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($747.5 million vs $719.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | LXRX |
|---|---|---|
| Share price | $22.09 | $1.68 |
| Market cap | $719.15M | $747.53M |
| 1-day change | -0.09% | -4.55% |
| YTD return | -52.29% | +53.04% |
| 1-year return | -33.48% | +23.08% |
| 5-year return | +5.29% | -71.43% |
| P/E ratio (TTM) | 17.39 | — |
| Forward P/E | 3.33 | — |
| EPS (TTM) | $1.27 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $2.68 |
| 52-week low | $21.43 | $1.10 |
| Distance from 52-week high | -56.50% | -37.31% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +121.82% | +170.83% |
| Average volume | 749.33K | 2.91M |
| Shares outstanding | 32.56M | 444.96M |
| Employees | 423 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed COLL by 56.6 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
COLL vs LXRX FAQ
Which is bigger, Collegium Pharmaceutical or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $747.53M compared with $719.15M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or LXRX?
LXRX returned +23.08% over the past 12 months, compared with -33.48% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.